The company was founded in 2005 and is a high-tech enterprise dedicated to the development and production of high-value medical devices with animal-derived implants. The company independently develops animal tissue engineering and original chemical modification treatment technology, and has now been approved for 17 Class III medical device products. The company is a leading domestic research and development platform enterprise for animal-derived implantation medical devices. The products cover the three major fields of heart valve replacement and repair, interventional treatment of congenital heart disease, and surgical soft tissue repair. The company is a technology-leading research and development platform enterprise for animal-derived implantation medical devices in China. Its products cover the three major fields of heart valve replacement and repair, interventional treatment of congenital heart disease implants, and surgical soft tissue repair. The company's products include heart valve replacement and repair, interventional treatment for congenital heart disease implants, and surgical soft tissue repair. Corporate honors: Silver Award at the 12th Beijing Invention and Innovation Competition, Beijing Science and Technology Third Prize - Industrialization of Surgical Biological Patches, Beijing Honest Creation of Enterprises, etc.
No Data